Indocyangreen Elimination in Cirrhosis and Acute Liver Failure

Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00245310

Enrollment

Registered

2005-10-27

Start date

2005-10-31

Completion date

2010-10-31

Last updated

2010-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Liver Failure, Liver Cirrhosis

Keywords

ICG clearance, liver cirrhosis, acute liver failure, prognosis

Brief summary

Indocyangreen (ICG)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion. The ICG-clearance will be evaluated as a prognostic marker in liver disease.

Detailed description

patients with acute liver failure or advanced liver disease will be studied. ICG-clearance will be correlated with established clinical scores and outcome.

Interventions

PROCEDUREIndocyangreen (ICG) clearance

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* acute liver failure OR end-stage liver disease * normal hepatic perfusion by doppler ultrasound

Exclusion criteria

* portal vein thrombosis * allergy to ICG or iodine * thyroid disease

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026